Moderna (NasdaqGS:MRNA) has reached a global settlement with Genevant Sciences and Arbutus Biopharma over lipid nanoparticle technology used in its Covid 19 vaccines. The agreement includes a ...
Hepatitis C virus (HCV) infects an estimated 50 million people worldwide, according to the World Health Organization, and remains a leading cause of cirrhosis and liver cancer. While antiviral drugs ...
Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, ...
Read more about Nanoparticle and AI-driven vaccines target broad protection against emerging threats on Devdiscourse ...
Cancer vaccines have long sounded like science fiction, but a new wave of nanoparticle research is pushing that idea closer to everyday reality. By packaging tumor signals into tiny, engineered ...
By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...
Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing Pfizer (PFE.N), opens new tab access to its technology that boosts immune responses to vaccines for use in up to ...
US health regulators have given final approval to Novavax's COVID vaccine after an unusual delay and have placed new restrictions on the jab, the pharmaceutical company announced Monday. The US drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results